Compounds for reversing drug resistance
AssigneeSolvo Biotechnology
InventorsBalazs Sarkadi, Janos Seprodi, Orsolya Csuka, Maria Magocsi, Imre Mezo, Istvan Palyi, Istvan Teplan, Zsolt Vadasz, Borbala Vincze
Life of this patent
Estimating the term…
Loading patent…
AssigneeSolvo Biotechnology
InventorsBalazs Sarkadi, Janos Seprodi, Orsolya Csuka, Maria Magocsi, Imre Mezo, Istvan Palyi, Istvan Teplan, Zsolt Vadasz, Borbala Vincze
Estimating the term…
The invention features novel peptide derivatives called Reversins, and provides for their use in a method of reducing the activity of the multi-drug transporter protein MDR1 in order to overcome multidrug resistance in a mammal. The peptide derivatives are of the formula (I) X1n-X2-X3(X4)n-X5, wherein n is 0 or 1, and each n is the same or different; X1 is BOC, BOC-Asu, Z-Asu, benzyloxycarbonyl, Glu(OBzl)-OBzl, Trp-OMe, Trp-Phe-OMe, Phe-Trp-OMe, Phe-Phe-OtBu, Trp-Trp-OtBu, indoloacetyl, benzoyl, an alkylanine of 1-4 carbons, dibenzylamide, tryptamide, 1-amino-adamantine, aminomethylcyclohexane, indoline, phenylethylamide or dicyclohexylamide; X2 is Glu(OBzl), Asp(OBzl), succinyl, O,O-dibenzoyltartaroyl, diphenoyl, muconyl, Thx, Cpa, Asu, Nal, Pen, Phg, Dbt, Lys(BOC), Lys(Z), Cys(Bzl), Thr(Bzl), Glu(OtBu), tert.-Leu, Leu, Nle, Pro, Phe, Tyr(Bzl), or Ser(Bal); X3 is Asp, Asu, Lys, Glu, Trp, Thx, Cpa, Nal, Pen, Phg, Dbt, Glu(OtBu), tert.-Leu, Leu, Nle, Pro, Tyr, Phe, or Tyr(Bzl); X4 is BOC-Glu(OBzl), Glu(OBzl), Asu, OBzl, Bzl, BOC, BOC-Lys(BOC), Z-Glu(OtBu), Asp(OBzl), Asp(OBz)-OBzl, benzyloxycarbonyl, O-(cyclo-hexyl), fluorenylmethyl ester, Glu(OtBu), Glu(OtBu)-OBzl, 1-amino-adamantine, aminomethylcyclohexane, indoline, phenylethylarnide, or dicyclohexylamide; and X5 is OMe, OBzl, OtBu, Phe-OMe, -O-(cyclohexyl), Trp-OMe, (chlorophenyl)-isobutylamide, fluorenylmethyl ester, ONp, 1-aminoadamantane, aminomethylcyclohexane, indoline, phenylethylamide, or dicyclohexylamide.
A method for reducing the activity of the multidrug transporter protein in a mammal, said method comprising administering to said mammal an effective amount of a compound BOC-Asp(OBzl)-Lys(Z)-OtBu, or Nα,Nε-bis[BOC-Glu(OBzl)]-Lys-OMe.
A peptide compound selected from the group consisting of BOC-Asp(OBzl)-Lys(Z)-OtBu, succinyl-bis[Glu(OBzl)-OBzl], Z-D-Glu-(OBzl)-D-Asp(OBzl)-OBzl, DBTA-bis(D-Phe-Trp-OMe), DBTA-[Glu(O-Bzl)2], Nα,Nε-bis[BOC-Glu(OBzl)]-Lys-OMe, BOC-Tyr(Bzl)-Tyr-(Bzl)-OMe, BOC-D-Ser(Bzl)-Lys(Z)-OtBu, BOC-Glu(OBzl)-Lys(z)-OtBu, Nα,Nε-bis[BOC-Lys(BOC)]Lys-OMe and Nα,Nε-bis[Z-Glu(OtBu)]Lys-OMe.
Dependencies are inferred from the claim text.